ruxolitinib
ruxolitinib
Overview
Ruxolitinib is a selective, orally administered small-molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), two tyrosine kinases that play central roles in cytokine signaling through the JAK/STAT pathway. By blocking JAK1 and JAK2 activity, ruxolitinib suppresses downstream signaling through transcription factors such as STAT1 and STAT5A, thereby attenuating the aberrant cytokine-driven inflammation and cell proliferation that underlies several hematologic malignancies and immune-mediated disorders. It was among the first JAK inhibitors to receive regulatory approval and belongs to the broader class of Janus kinase inhibitors that has transformed the management of myeloproliferative neoplasms and inflammatory conditions.
Ruxolitinib is approved for the treatment of intermediate- or high-risk myelofibrosis (MF), polycythemia vera (PV) in patients who are resistant to or intolerant of hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease (GVHD). Its mechanism centers on the inhibition of constitutively active or mutant JAK2 (including JAK2 V617F), as well as JAK2 gain-of-function mutations, which drive pathological activation of the JAK2/STAT3 signaling pathway and CD44/JAK2/STAT3 signaling pathway in malignant hematopoietic cells. By dampening these cascades, ruxolitinib reduces splenomegaly, alleviates disease-related symptoms, and modulates immune responses relevant to both cancer and autoimmune disease contexts.
Focus of Latest Publications
Recent publications on ruxolitinib have focused largely on its role as a Janus kinase inhibitor in myeloproliferative and hyperinflammatory disorders, with additional interest in immune-mediated complications and combination regimens. In polycythaemia vera, a prospective real-world German study (PaVe) evaluated ruxolitinib in routine practice and reported improvements in hematocrit, leukocyte, and platelet counts, with no new safety concerns and overall support for its use as an effective second-line treatment in patients resistant to or intolerant of hydroxyurea. In myelofibrosis, several studies examined ruxolitinib-based strategies, including real-world treatment patterns in Japan, where all Janus kinase inhibitor-treated patients received ruxolitinib, and combination approaches intended to improve spleen and symptom control.
Combination therapy studies in myelofibrosis included navitoclax plus ruxolitinib in JAK inhibitor-naïve patients and selinexor plus ruxolitinib in a phase 1 study. The navitoclax study reported spleen volume reduction, symptom improvement, bone marrow fibrosis improvement, and anemia responses with a tolerable safety profile, while the selinexor study found no dose-limiting toxicities and identified selinexor 60 mg with ruxolitinib as the recommended phase 3 dose based on safety and efficacy signals. Another real-world study examined high-dose ruxolitinib exposure in myelofibrosis, reflecting ongoing interest in feasibility and long-term treatment intensity. A separate report also noted that momelotinib after ruxolitinib failure remains an area of limited real-world evidence.
Beyond myeloproliferative disease, ruxolitinib was studied in immune dysregulation and inflammatory syndromes. In steroid-refractory acute graft-versus-host disease, mechanistic work linked clinical response to ruxolitinib with reduced STAT1 activation, restoration of glucocorticoid receptor expression, and contraction of expanded CD28+ CD8+ effector-memory T cells, supporting a pathway-targeted role in steroid resistance. Case-based reports described successful use of ruxolitinib for refractory ciltacabtagene autoleucel-associated diarrhea after chimeric antigen receptor T cell therapy, with rapid clinical improvement in treated patients and histopathologic response in biopsied cases. Another case report described effective treatment of refractory TAFRO-like syndrome using ruxolitinib combined with ropeginterferon alfa-2b in a patient with a history of polycythemia vera and JAK2 V617F.
Additional publications explored ruxolitinib in hematologic malignancy and pediatric hyperinflammation. In childhood B-cell precursor acute lymphoblastic leukemia with JAK2 gain-of-function mutations, ruxolitinib selectively reduced STAT5 phosphorylation and induced measurable biochemical changes in mutant but not wild-type cells, with Raman spectroscopy proposed as a non-destructive method to monitor treatment response. In pediatric hemophagocytic lymphohistiocytosis, ruxolitinib was discussed as part of targeted therapy alongside emapalumab plus conventional therapy, reflecting growing interest in cytokine-directed approaches for severe hyperinflammatory syndromes.